Friday, June 8, 2012
Curis Inc., of Lexington, Mass., said data from an investigator-sponsored trial demonstrating Erivedge's (vismodegib) proof-of-concept efficacy in treating basal cell nevus syndrome and surgically eligible basal cell carcinoma (BCC) were published in the current edition of The New England Journal of Medicine, along with a separate article reporting the results of a pivotal Phase II trial in advanced BCC.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.